News to know
Whether it’s health or education policy changes or new research about learning and thinking differences, we help you make sense of the headlines — so you can make informed decisions for you and your family.
Trump administration splits special education oversight between HHS and DOJ
Featured stories
FDA approves Simtriyo (centanafadine), a ‘first of its kind’ ADHD medication
The Food and Drug Administration (FDA) just approved Simtriyo (centanafadine), a new norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system stimulant. The medication treats ADHD in adults, teens, and children ages 6 and up weighing at least 44 pounds. Most stimulant and non-stimulant ADHD medications raise the levels of two different brain chemicals related to A
How the Trump administration is changing federal oversight of special education
Updated on July 30 with the latest news from Congress. On June 16, 2026, the U.S. Department of Education announced that it’s splitting oversight of special education between the U.S. Department of Health and Human Services (HHS) and the Department of Justice (DOJ). Special education exists so that students with disabilities can participate, learn, and make progress in school alongside their pee
Stay informed
Get updates on health, education policy, and learning research straight to your inbox.
ADHD in the news
Education news
Help keep lifelong support and expert resources free and accessible for all.
